The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro (2020)

Peer-Reviewed Study · Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM · June 2020

Caly L et al., 2020-06: Laboratory study in which a single dose of ivermectin added to SARS-CoV-2-infected Vero-hSLAM cells reduced viral RNA about 5000-fold at 48 hours.

a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h

Caly L et al., 2020-06: Laboratory study in which a single dose of ivermectin added to SARS-CoV-2-infected Vero-hSLAM cells reduced viral RNA about 5000-fold at 48 hours. Cell-line study (Vero-hSLAM), no human subjects, Australia (Monash University and the Australian Centre for Disease Preparedness). Ivermectin added 2 h post infection; ~5000-fold reduction in viral RNA at 48 h by RT-qPCR; the paper states clinical trials were warranted. Comparator: untreated infected cells. Funder and conflicts: no funding or disclosure statement is carried in the PubMed record; the paper is a short communication. No maker involved. This is in-vitro evidence only and the authors do not claim clinical benefit , the concentration used is far above usual human plasma levels, a point made in later pharmacokinetic critiques. Study type: lab.